File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: TORS for Benign Disease
| Title | TORS for Benign Disease |
|---|---|
| Authors | |
| Issue Date | 2016 |
| Citation | 6th International Robotic Surgery Symposium. Seoul, South Korea. 15-16 October 2016 How to Cite? |
| Abstract | The FDA first approved the da Vinci robot for use in the head and neck area in 2009 for resection of early (T1-T2) cancers of the oropharynx, larynx and hypopharynx after reviewing the safety and efficacy of transoral robotic surgery (TORS) from multi-center studies. TORS is actually also a effective minimally invasive surgical option for managing benign disease in the upper aerodigestive tract. TORS has been successfully applied in removing benign tumors in the oropharynx, larynx and hypopharynx. TORS resection of parapharyngeal space tumors has a distinct advantage over open transcervical approach and is gaining popularity. Finally, pioneered by Prof. Claudio Vincini, TORS has been used extensively for volume reduction in the base of tongue for obstructive sleep apnea. The safety and efficacy data in the literature cumulated the approval of TORS for benign disease in the upper-aerodigestive tract in 2014. TORS is now a option for managing various benign condition in the upper-aerodigestive tract with distinct advantages over other endoscopic surgical techniques |
| Persistent Identifier | http://hdl.handle.net/10722/283829 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsang, RKY | - |
| dc.date.accessioned | 2020-07-13T04:13:57Z | - |
| dc.date.available | 2020-07-13T04:13:57Z | - |
| dc.date.issued | 2016 | - |
| dc.identifier.citation | 6th International Robotic Surgery Symposium. Seoul, South Korea. 15-16 October 2016 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/283829 | - |
| dc.description.abstract | The FDA first approved the da Vinci robot for use in the head and neck area in 2009 for resection of early (T1-T2) cancers of the oropharynx, larynx and hypopharynx after reviewing the safety and efficacy of transoral robotic surgery (TORS) from multi-center studies. TORS is actually also a effective minimally invasive surgical option for managing benign disease in the upper aerodigestive tract. TORS has been successfully applied in removing benign tumors in the oropharynx, larynx and hypopharynx. TORS resection of parapharyngeal space tumors has a distinct advantage over open transcervical approach and is gaining popularity. Finally, pioneered by Prof. Claudio Vincini, TORS has been used extensively for volume reduction in the base of tongue for obstructive sleep apnea. The safety and efficacy data in the literature cumulated the approval of TORS for benign disease in the upper-aerodigestive tract in 2014. TORS is now a option for managing various benign condition in the upper-aerodigestive tract with distinct advantages over other endoscopic surgical techniques | - |
| dc.language | eng | - |
| dc.relation.ispartof | 6th International Robotic Surgery Symposium. Seoul, 2016 | - |
| dc.title | TORS for Benign Disease | - |
| dc.type | Conference_Paper | - |
| dc.identifier.email | Tsang, RKY: rkytsang@hku.hk | - |
| dc.identifier.authority | Tsang, RKY=rp01386 | - |
| dc.identifier.hkuros | 271096 | - |